RxDoctor Payments Data

Arturo Sanchez, OD

Optometrist · Mission, TXNPI 1932870383

Payments from drug & device makers

$3,037in general payments, 2019–2025

Across 49 payments — averaging $61.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$899
  • Biotissue Holdings Inc.$725
  • Bausch & Lomb Americas Inc.$392
  • Tarsus Pharmaceuticals, Inc.$354
  • AbbVie$352
  • Amgen$125
  • plus $190 from 5 others

What the payments were for

  • Food & beverage$3,037100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,037 in reported general payments places this provider in the 80th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$38,889
Medicare patients
206
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost153$68,094
RestasisCyclosporine60$61,639
XiidraLifitegrast14$21,331
RocklatanNetarsudil Mesylat/Latanoprost48$16,393
Alphagan PBrimonidine Tartrate56$14,662
VyzultaLatanoprostene Bunod33$13,841
Brimonidine Tartrate92$9,497
Cyclosporine17$8,602
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol66$8,502
CombiganBrimonidine Tartrate/Timolol28$7,904
SimbrinzaBrinzolamide/Brimonidine Tart28$5,622
Latanoprost468$5,434
Ketorolac Tromethamine126$3,214
Prednisolone Acetate54$2,231
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha161$1,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$352$152,299297 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$392$35,17347 claims
Aerie Pharmaceuticals, Inc.Rocklatan$110$16,39348 claims
AlconSimbrinza$899$5,62228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Mission

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →